No Data
No Data
No Data
No Data
No Data
SAB Biotherapeutics Price Target Maintained With a $6.00/Share by HC Wainwright & Co.
SAB Biotherapeutics Price Target Maintained With a $6.00/Share by HC Wainwright & Co.
Dow JonesApr 16 13:38 ET
Analysts Offer Insights on Healthcare Companies: SAB Biotherapeutics (SABS) and Compass Therapeutics (CMPX)
TipRanksApr 16 10:00 ET
Express News | Chardan Capital Maintains Buy on SAB Biotherapeutics, Maintains $25 Price Target
Moomoo 24/7Apr 16 07:41 ET
Express News | SAB Biotherapeutics' Has Completed Dosing The Third Cohort For Phase 1 Study Of SAB-142 In Healthy Volunteers And Participants With Type 1 Diabetes With No Observation Of Serum Sickness Thus Far
Moomoo 24/7Apr 16 07:17 ET
Express News | SAB Biotherapeutics: Completed Dosing Third Cohort for SAB-142 With No Observation of Serum Sickness Thus Far
Moomoo 24/7Apr 16 07:15 ET
Express News | SAB Biotherapeutics Provides SAB-142 Trial Update
Moomoo 24/7Apr 16 07:15 ET
No Data
No Data
Piggy Bank Trader : I transferred the money from another brokerage to my bank and sending it back. 3040 shares is good enough. I’m not avg down.